Lingjie Shen, Erik Visser, Felice van Erning, Gijs Geleijnse, Maurits Kaptein
{"title":"验证因果效应估计值的两步框架","authors":"Lingjie Shen, Erik Visser, Felice van Erning, Gijs Geleijnse, Maurits Kaptein","doi":"10.1002/pds.5873","DOIUrl":null,"url":null,"abstract":"Background: Comparing causal effect estimates obtained using observational data to those obtained from the gold standard (i.e., randomized controlled trials [RCTs]) helps assess the validity of these estimates. However, comparisons are challenging due to differences between observational data and RCT generated data. The unknown <jats:italic>treatment assignment</jats:italic> <jats:italic>mechanism</jats:italic> in the observational data and varying <jats:italic>sampling mechanisms</jats:italic> between the RCT and the observational data can lead to confounding and sampling bias, respectively.Aims: The objective of this study is to propose a two‐step framework to validate causal effect estimates obtained from observational data by adjusting for both mechanisms.Materials and Methods: An estimator of causal effects related to the two mechanisms is constructed. A two‐step framework for comparing causal effect estimates is derived from the estimator. An R package <jats:italic>RCTrep</jats:italic> is developed to implement the framework in practice.Results: A simulation study is conducted to show that using our framework observational data can produce causal effect estimates similar to those of an RCT. A real‐world application of the framework to validate treatment effects of adjuvant chemotherapy obtained from registry data is demonstrated.Conclusion: This study constructs a framework for comparing causal effect estimates between observational data and RCT data, facilitating the assessment of the validity of causal effect estimates obtained from observational data.","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"35 1","pages":"e5873"},"PeriodicalIF":2.4000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Two‐Step Framework for Validating Causal Effect Estimates\",\"authors\":\"Lingjie Shen, Erik Visser, Felice van Erning, Gijs Geleijnse, Maurits Kaptein\",\"doi\":\"10.1002/pds.5873\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Comparing causal effect estimates obtained using observational data to those obtained from the gold standard (i.e., randomized controlled trials [RCTs]) helps assess the validity of these estimates. However, comparisons are challenging due to differences between observational data and RCT generated data. The unknown <jats:italic>treatment assignment</jats:italic> <jats:italic>mechanism</jats:italic> in the observational data and varying <jats:italic>sampling mechanisms</jats:italic> between the RCT and the observational data can lead to confounding and sampling bias, respectively.Aims: The objective of this study is to propose a two‐step framework to validate causal effect estimates obtained from observational data by adjusting for both mechanisms.Materials and Methods: An estimator of causal effects related to the two mechanisms is constructed. A two‐step framework for comparing causal effect estimates is derived from the estimator. An R package <jats:italic>RCTrep</jats:italic> is developed to implement the framework in practice.Results: A simulation study is conducted to show that using our framework observational data can produce causal effect estimates similar to those of an RCT. A real‐world application of the framework to validate treatment effects of adjuvant chemotherapy obtained from registry data is demonstrated.Conclusion: This study constructs a framework for comparing causal effect estimates between observational data and RCT data, facilitating the assessment of the validity of causal effect estimates obtained from observational data.\",\"PeriodicalId\":19782,\"journal\":{\"name\":\"Pharmacoepidemiology and Drug Safety\",\"volume\":\"35 1\",\"pages\":\"e5873\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacoepidemiology and Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pds.5873\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.5873","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
A Two‐Step Framework for Validating Causal Effect Estimates
Background: Comparing causal effect estimates obtained using observational data to those obtained from the gold standard (i.e., randomized controlled trials [RCTs]) helps assess the validity of these estimates. However, comparisons are challenging due to differences between observational data and RCT generated data. The unknown treatment assignmentmechanism in the observational data and varying sampling mechanisms between the RCT and the observational data can lead to confounding and sampling bias, respectively.Aims: The objective of this study is to propose a two‐step framework to validate causal effect estimates obtained from observational data by adjusting for both mechanisms.Materials and Methods: An estimator of causal effects related to the two mechanisms is constructed. A two‐step framework for comparing causal effect estimates is derived from the estimator. An R package RCTrep is developed to implement the framework in practice.Results: A simulation study is conducted to show that using our framework observational data can produce causal effect estimates similar to those of an RCT. A real‐world application of the framework to validate treatment effects of adjuvant chemotherapy obtained from registry data is demonstrated.Conclusion: This study constructs a framework for comparing causal effect estimates between observational data and RCT data, facilitating the assessment of the validity of causal effect estimates obtained from observational data.
期刊介绍:
The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report.
Particular areas of interest include:
design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology;
comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world;
methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology;
assessments of harm versus benefit in drug therapy;
patterns of drug utilization;
relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.